IFNB1 and myeloid sarcoma: Furthermore, the interferon betas are acknowledged as standard of care and have recently acted as an active comparator in two different large scale prospective randomized controlled clinical trials testing new MS therapies (Hauser et al., 2017; Kappos, Wiendl, et al., 2015).